31 October 2021 - Blood cancer patients will be among those to benefit with better access to medicine under the Pharmaceutical Benefits Scheme.

Until now, Australians with multiple myeloma have received Darzalex by infusion which typically takes several hours to administer per month in a hospital or infusion centre but the new listing is for the treatment to be injected in 3-5 minutes saving patients an estimated 70 hours a year for treatment.

Read Daily Telegraph article